Humacyte Stock Options

HUMA Stock  USD 5.10  0.08  1.54%   
Humacyte's latest option contracts expiring on January 17th 2025 are carrying combined implied volatility of 3.03. The total put volume is at 76.0, with calls trading at the volume of 528. This yields a 0.14 put-to-call volume ratio. The Humacyte option chain provides detailed quote and price information for the current Humacyte option contracts. It shows all of Humacyte's listed puts, calls, expiration dates, strike prices, and other pricing information.

In The Money vs. Out of Money Option Contracts on Humacyte

Analyzing Humacyte's in-the-money options over time can help investors to take a profitable long position in Humacyte regardless of its overall volatility. This is especially true when Humacyte's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Humacyte's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Humacyte's stock while costing only a fraction of its price.
Humacyte's stock options are financial instruments that give investors the right to buy or sell shares of Humacyte common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Humacyte stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Humacyte's stock price goes up or down, the stock options follow.
At present, Humacyte's Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 196.8 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 61.4 M.

Humacyte In The Money Call Balance

When Humacyte's strike price is surpassing the current stock price, the option contract against Humacyte stock is said to be in the money. When it comes to buying Humacyte's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Humacyte are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Humacyte Current Options Market Mood

Humacyte's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Humacyte Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Volume

Unfortunately, most Humacyte's options investors are not very successful. Humacyte's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Humacyte contract

Base on the Rule 16, the options market is currently suggesting that Humacyte will have an average daily up or down price movement of about 0.19% per day over the life of the 2025-01-17 option contract. With Humacyte trading at USD 5.1, that is roughly USD 0.009658. If you think that the market is fully incorporating Humacyte's daily price movement you should consider buying Humacyte options at the current volatility level of 3.03%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing Humacyte options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Humacyte calls. Remember, the seller must deliver Humacyte stock to the call owner when a call is exercised.

Humacyte Option Chain

When Humacyte's strike price is surpassing the current stock price, the option contract against Humacyte stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Humacyte's option chain is a display of a range of information that helps investors for ways to trade options on Humacyte. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Humacyte. It also shows strike prices and maturity days for a Humacyte against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
HUMA250117C0000050000.52.8 - 6.52.8In
Call
HUMA250117C0000100001.01.5 - 6.21.5In
Call
HUMA250117C0000150001.53.1 - 5.83.1In
Call
HUMA250117C0000250002.50.65 - 2.92.5In
Call
HUMA250117C0000200002.02.7 - 3.13.0In
Call
HUMA250117C0000300003.01.95 - 2.351.95In
Call
HUMA250117C0000350003.51.7 - 1.951.7In
Call
HUMA250117C0000500005.01.05 - 1.71.15Out
Call
HUMA250117C0000750007.50.25 - 0.60.6Out
Call
HUMA250117C00010000010.00.05 - 1.50.05Out
 Put
HUMA250117P0000050000.50.0 - 0.750.75Out
 Put
HUMA250117P0000100001.00.0 - 0.050.05Out
 Put
HUMA250117P0000150001.50.0 - 0.10.1Out
 Put
HUMA250117P0000250002.50.05 - 0.70.05Out
 Put
HUMA250117P0000200002.00.15 - 0.20.15Out
 Put
HUMA250117P0000300003.00.25 - 0.450.4Out
 Put
HUMA250117P0000350003.50.45 - 0.60.6Out
 Put
HUMA250117P0000500005.00.0 - 2.01.13In
 Put
HUMA250117P0000750007.51.8 - 4.31.8In
 Put
HUMA250117P00010000010.04.5 - 6.34.5In

Humacyte Market Cap Over Time

   Market Cap   
       Timeline  

Humacyte Total Stockholder Equity

Total Stockholder Equity

16.36 Million

At present, Humacyte's Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting.

Humacyte Corporate Management

Harold AltersonSenior QualityProfile
Sabrina OsborneExecutive PeopleProfile
Dale SanderChief CFOProfile
William ScheesseleChief OfficerProfile
Yang MDChief OfficerProfile
Shamik MDChief OfficerProfile
When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(8.51)
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.